{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:00:41Z","timestamp":1793656841648,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068633"],"award-info":[{"award-number":["UM1AI068633"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068615"],"award-info":[{"award-number":["UM1AI068615"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI106707"],"award-info":[{"award-number":["UM1AI106707"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Effective use of oral pre-exposure prophylaxis (PrEP) has been low among adolescent girls and young women (AGYW) in Eastern and Southern Africa, partly due to stigma and opposition from key influencers. Understanding AGYW\u2019s experiences of disclosure of different PrEP modalities to key influencers may inform strategies to motivate uptake and adherence. We analyzed qualitative in-depth interviews and focus group discussions data from 119 participants in the MTN-034\/REACH (<jats:bold>R<\/jats:bold>eversing the <jats:bold>E<\/jats:bold>pidemic in <jats:bold>A<\/jats:bold>frica with <jats:bold>C<\/jats:bold>hoices in <jats:bold>H<\/jats:bold>IV Prevention) study of oral PrEP and the dapivirine vaginal ring (ring) to explore AGYW\u2019s disclosure experiences. We found that AGYW disclosure experiences varied across influencers and product type. The ring was disclosed less often to most influencers, except partners, because it was discreet. Oral PrEP was disclosed more often, because pills were more common and to avoid HIV stigma given that oral PrEP resembled HIV treatment. Ultimately, disclosure typically led most key influencers to support product use through reminders and encouragement. While disclosure yielded positive support from influencers, further community awareness of both PrEP products is essential to reduce potential opposition and perceived stigma.<\/jats:p><jats:p><jats:bold>Clinical Trial Number<\/jats:bold>: NCT03593655.<\/jats:p>","DOI":"10.1007\/s10461-023-04109-w","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:01:47Z","timestamp":1688212907000},"page":"3941-3951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Adolescent Girls and Young Women\u2019s Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9277-967X","authenticated-orcid":false,"given":"Alinda M.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millicent","family":"Atujuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyanda","family":"Tenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miria","family":"Chitukuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Kemigisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ngure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"van der Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Szydlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Soto-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"4109_CR1","unstructured":"UNAIDS., Miles to go: closing gaps, breaking barriers, righting injustices. 2018."},{"issue":"1","key":"4109_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-6405-10-30","volume":"10","author":"G Ramjee","year":"2013","unstructured":"Ramjee G, Daniels B. Women and HIV in sub-saharan Africa. AIDS Res therapy. 2013;10(1):1\u20139.","journal-title":"AIDS Res therapy"},{"key":"4109_CR3","first-page":"283","volume-title":"Communities at the centre, defending rights, breaking barriers, reaching people with HIV services, UNAIDS joint United Nations programme on HIV. Update","author":"A Global","year":"2019","unstructured":"Global A. Communities at the centre, defending rights, breaking barriers, reaching people with HIV services, UNAIDS joint United Nations programme on HIV. Update. AIDS Geneva: UNAIDS; 2019. pp. 283\u201393."},{"issue":"11","key":"4109_CR4","doi-asserted-by":"publisher","first-page":"e1521","DOI":"10.1016\/S2214-109X(19)30410-3","volume":"7","author":"I Birdthistle","year":"2019","unstructured":"Birdthistle I, et al. Recent levels and trends in HIV incidence rates among adolescent girls and young women in ten high-prevalence african countries: a systematic review and meta-analysis. The Lancet Global Health. 2019;7(11):e1521\u201340.","journal-title":"The Lancet Global Health"},{"issue":"Supplement3","key":"4109_CR5","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1086\/651483","volume":"50","author":"QA Karim","year":"2010","unstructured":"Karim QA, Sibeko S, Baxter C. Preventing HIV infection in women: a global health imperative. Clin Infect Dis. 2010;50(Supplement3):S122\u20139.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4109_CR6","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner VA, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973\u201383.","journal-title":"AIDS"},{"issue":"5","key":"4109_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, et al. Antiretroviral preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med. 2012;367(5):423\u201334.","journal-title":"N Engl J Med"},{"issue":"13","key":"4109_CR8","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1097\/QAD.0b013e3283629037","volume":"27","author":"PM Murnane","year":"2013","unstructured":"Murnane PM, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. Aids. 2013;27(13):2155\u201360.","journal-title":"Aids"},{"issue":"5","key":"4109_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, et al. Antiretroviral prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"issue":"22","key":"4109_CR10","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, et al. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. N Engl J Med. 2016;375(22):2133\u201343.","journal-title":"N Engl J Med"},{"issue":"22","key":"4109_CR11","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, et al. Use of a Vaginal Ring containing dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016;375(22):2121\u201332.","journal-title":"N Engl J Med"},{"key":"4109_CR12","unstructured":"Organization WH. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization; 2021."},{"key":"4109_CR13","doi-asserted-by":"crossref","unstructured":"Scorgie F, et al. Disclosure of PrEP use by young women in South Africa and Tanzania: qualitative findings from a demonstration project. Volume 23. Culture, Health & Sexuality; 2021. pp. 257\u201372. 2.","DOI":"10.1080\/13691058.2019.1703041"},{"issue":"3S2","key":"4109_CR14","doi-asserted-by":"publisher","first-page":"19146","DOI":"10.7448\/IAS.17.3.19146","volume":"17","author":"A van der Straten","year":"2014","unstructured":"van der Straten A, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(3S2):19146.","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"4109_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s10461-014-0950-5","volume":"19","author":"ET Montgomery","year":"2015","unstructured":"Montgomery ET, et al. Male Partner Influence on Women\u2019s HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the importance of \u201cUnderstanding. AIDS Behav. 2015;19(5):784\u201393.","journal-title":"AIDS Behav"},{"issue":"2","key":"4109_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10461-016-1609-1","volume":"21","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, et al. Misreporting of product adherence in the MTN-003\/VOICE Trial for HIV Prevention in Africa: participants\u2019 explanations for dishonesty. AIDS Behav. 2017;21(2):481\u201391.","journal-title":"AIDS Behav"},{"issue":"3","key":"4109_CR17","doi-asserted-by":"publisher","first-page":"e25463","DOI":"10.1002\/jia2.25463","volume":"23","author":"J Velloza","year":"2020","unstructured":"Velloza J, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23(3):e25463.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"4109_CR18","doi-asserted-by":"publisher","first-page":"e0248307","DOI":"10.1371\/journal.pone.0248307","volume":"16","author":"D Giovenco","year":"2021","unstructured":"Giovenco D, et al. Experiences of oral pre-exposure prophylaxis (PrEP) use disclosure among south african adolescent girls and young women and its perceived impact on adherence. PLoS ONE. 2021;16(3):e0248307.","journal-title":"PLoS ONE"},{"issue":"1","key":"4109_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12981-020-00310-2","volume":"17","author":"SE Nakasone","year":"2020","unstructured":"Nakasone SE, et al. They have this not care \u2013 don\u2019t care attitude:\u201d a mixed methods study evaluating Community readiness for oral PrEP in adolescent girls and Young Women in a rural area of South Africa. AIDS Res Therapy. 2020;17(1):55.","journal-title":"AIDS Res Therapy"},{"issue":"4","key":"4109_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10461-021-03455-x","volume":"26","author":"D Giovenco","year":"2022","unstructured":"Giovenco D, et al. The Effect of PrEP Use Disclosure on Adherence in a cohort of adolescent girls and Young Women in South Africa. AIDS Behav. 2022;26(4):1007\u201316.","journal-title":"AIDS Behav"},{"issue":"4","key":"4109_CR21","doi-asserted-by":"publisher","first-page":"e0125458","DOI":"10.1371\/journal.pone.0125458","volume":"10","author":"A Corneli","year":"2015","unstructured":"Corneli A, et al. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS ONE. 2015;10(4):e0125458.","journal-title":"PLoS ONE"},{"issue":"12","key":"4109_CR22","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1007\/s10461-021-03286-w","volume":"25","author":"MCD Stoner","year":"2021","unstructured":"Stoner MCD, et al. The influence of Perceived Dapivirine Vaginal Ring effectiveness on Social Disclosure and Ring Adherence. AIDS Behav. 2021;25(12):4169\u201379.","journal-title":"AIDS Behav"},{"issue":"8","key":"4109_CR23","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/QAD.0000000000001452","volume":"31","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159.","journal-title":"AIDS"},{"key":"4109_CR24","doi-asserted-by":"crossref","unstructured":"Nyblade L, et al. Perceived, anticipated and experienced stigma: exploring manifestations and implications for young people\u2019s sexual and reproductive health and access to care in North-Western Tanzania. Volume 19. Culture, health & sexuality; 2017. pp. 1092\u2013107. 10.","DOI":"10.1080\/13691058.2017.1293844"},{"issue":"1","key":"4109_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4081\/qrmh.2018.7062","volume":"2","author":"KS Hall","year":"2018","unstructured":"Hall KS, et al. Bad girl and unmet family planning need among sub-saharan african adolescents: the role of sexual and reproductive health stigma. Qualitative Res Med Healthc. 2018;2(1):55.","journal-title":"Qualitative Res Med Healthc"},{"issue":"2","key":"4109_CR26","doi-asserted-by":"publisher","first-page":"e0246717","DOI":"10.1371\/journal.pone.0246717","volume":"16","author":"N Jani","year":"2021","unstructured":"Jani N, et al. Relationship dynamics and anticipated stigma: key considerations for PrEP use among Tanzanian adolescent girls and young women and male partners. PLoS ONE. 2021;16(2):e0246717.","journal-title":"PLoS ONE"},{"issue":"S4","key":"4109_CR27","first-page":"71","volume":"24","author":"G Nair","year":"2021","unstructured":"Nair G, et al. Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study. J Int AIDS Soc. 2021;24(S4):71\u20132.","journal-title":"J Int AIDS Soc"},{"key":"4109_CR28","unstructured":"Ngure K et al. Choice and adherence to dapivirine ring or oral PrEP by young African women in REACH. in Conference on Retroviruses and Opportunistic Infections (CROI). 2022."},{"issue":"6","key":"4109_CR29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/COH.0b013e3283590632","volume":"7","author":"BS Mensch","year":"2012","unstructured":"Mensch BS, van der Straten A, Katzen LL. Acceptability in microbicide and PrEP trials: current status and a reconceptualization. Curr Opin HIV AIDS. 2012;7(6):534\u201341.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"4109_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/BF02506983","volume":"23","author":"MA Zimmerman","year":"1995","unstructured":"Zimmerman MA. Psychological empowerment: issues and illustrations. Am J Community Psychol. 1995;23(5):581\u201399.","journal-title":"Am J Community Psychol"},{"key":"4109_CR31","unstructured":"35 DV. Web application for managing, analyzing, and presenting qualitative and mixed method research data. 2018, SocioCultural Research Consultants, LLC Los Angeles, CA."},{"issue":"10","key":"4109_CR32","doi-asserted-by":"publisher","first-page":"e0258542","DOI":"10.1371\/journal.pone.0258542","volume":"16","author":"E Rousseau","year":"2021","unstructured":"Rousseau E, et al. Adolescent girls and young women\u2019s PrEP-user journey during an implementation science study in South Africa and Kenya. PLoS ONE. 2021;16(10):e0258542.","journal-title":"PLoS ONE"},{"issue":"7","key":"4109_CR33","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s10461-020-03145-0","volume":"25","author":"S O\u2019Rourke","year":"2021","unstructured":"O\u2019Rourke S, et al. The PrEP journey: understanding how internal drivers and external circumstances impact the PrEP trajectory of adolescent girls and Young Women in Cape Town, South Africa. AIDS Behav. 2021;25(7):2154\u201365.","journal-title":"AIDS Behav"},{"issue":"3","key":"4109_CR34","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1097\/QAI.0000000000002674","volume":"87","author":"Z Baker","year":"2021","unstructured":"Baker Z, et al. Qualitative study on the acceptability of and adherence to a Vaginal Ring for HIV Prophylaxis among adolescent girls. J Acquir Immune Defic Syndr. 2021;87(3):944\u201350.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"4109_CR35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/QAI.0000000000000702","volume":"70","author":"BA Chen","year":"2015","unstructured":"Chen BA, et al. Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: a double-blind randomized trial. J Acquir Immune Defic Syndr. 2015;70(3):242.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"4109_CR36","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.socscimed.2009.08.014","volume":"69","author":"NN Sahin-Hodoglugil","year":"2009","unstructured":"Sahin-Hodoglugil NN, et al. Degrees of disclosure: a study of women\u2019s covert use of the diaphragm in an HIV prevention trial in sub-saharan Africa. Soc Sci Med. 2009;69(10):1547\u201355.","journal-title":"Soc Sci Med"},{"issue":"5","key":"4109_CR37","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1007\/s10461-019-02707-1","volume":"24","author":"ST Roberts","year":"2020","unstructured":"Roberts ST, et al. Impact of Male Partner involvement on Women\u2019s adherence to the Dapivirine Vaginal Ring during a phase III HIV Prevention Trial. AIDS Behav. 2020;24(5):1432\u201342.","journal-title":"AIDS Behav"},{"issue":"2","key":"4109_CR38","doi-asserted-by":"publisher","first-page":"e89118","DOI":"10.1371\/journal.pone.0089118","volume":"9","author":"A van der Straten","year":"2014","unstructured":"van der Straten A, et al. Women\u2019s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118.","journal-title":"PLoS ONE"},{"issue":"8","key":"4109_CR39","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s10461-020-02799-0","volume":"24","author":"AWK Katz","year":"2020","unstructured":"Katz AWK, et al. The power of the Shared experience: MTN-020\/ASPIRE trial participants\u2019 descriptions of peer influence on acceptability of and adherence to the Dapivirine Vaginal Ring for HIV Prevention. AIDS Behav. 2020;24(8):2387\u201399.","journal-title":"AIDS Behav"},{"issue":"1","key":"4109_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jadohealth.2007.12.007","volume":"43","author":"LB Epstein","year":"2008","unstructured":"Epstein LB, et al. Adolescent experiences with the vaginal ring. J Adolesc Health. 2008;43(1):64\u201370.","journal-title":"J Adolesc Health"},{"key":"4109_CR41","doi-asserted-by":"crossref","unstructured":"Young A, et al. Religious leaders\u2019 role in pregnant and breastfeeding women\u2019s decision making and willingness to use biomedical HIV prevention strategies: a multi-country analysis. Volume 24. Culture, Health & Sexuality; 2022. pp. 612\u201326. 5.","DOI":"10.1080\/13691058.2021.1874054"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-023-04109-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-023-04109-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-023-04109-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T13:11:22Z","timestamp":1698153082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-023-04109-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["4109"],"URL":"https:\/\/doi.org\/10.1007\/s10461-023-04109-w","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"2 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Non-financial Interests"}},{"value":"The MTN-034 study protocol was approved by the institutional review boards at each study site and were overseen by the regulatory infrastructure of the Division of AIDS and the Microbicide Trials Network. All participants provided written informed consent before study participation, and IDI participants provided further verbal consent before being interviewed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent prior to study participation and in-depth interview participants provided further verbal consent before being interviewed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}